
2024年,位于澳大利亚悉尼的科技创业者保罗·康宁汉姆的爱犬罗茜被诊断出癌症。尽管罗茜接受了化疗与手术,肿瘤却仍未消退,病情也愈发严重。
于是他借助人工智能技术,在澳大利亚科学家的协助下,成功地研发出一款定制化mRNA抗癌疫苗。如今,罗茜体内的大部分肿瘤已经缩小,这只小狗又开始追逐野兔了。
据《澳大利亚人报》(Australian)报道,OpenAI旗下的ChatGPT建议采用免疫疗法,并指引康宁汉姆联系新南威尔士大学(University of New South Wales)的拉马乔蒂基因组学中心(Ramaciotti Center for Genomics)。
虽然康宁汉姆没有医学背景,但他是一名电气与计算机工程师,是Core Intelligence Technologies公司的联合创始人,还曾经担任澳大利亚数据科学与人工智能协会(Data Science and AI Association of Australia)的理事。
在与这所大学取得联系后,他说服了该校的研究人员提供协助,并向新南威尔士大学支付了罗茜的基因组测序费用。随后,他便开始深入研究这份基因数据。
“我向ChatGPT寻求帮助,并制定了具体的实施计划。”康宁汉姆告诉《澳大利亚人报》。
他还使用了谷歌(Google)DeepMind开发的人工智能工具AlphaFold,寻找可以作为潜在治疗靶点的突变蛋白。尽管他最终找到了一款与罗茜病情高度适配的免疫疗法药物,但制药公司却拒绝提供相关药剂。
随后,纳米医学领域先驱、新南威尔士大学RNA研究所(RNA Institute)的主任帕尔·索达森介入,利用康宁汉姆的数据,在不到两个月的时间内,研发出一款定制化mRNA疫苗。
“这是全球首款专为犬类设计的个性化抗癌疫苗。”索达森对《澳大利亚人报》表示,“作为癌症免疫治疗领域的前沿技术,该技术终会应用于人类疾病治疗。罗茜的案例给我们的启示是,借助mRNA技术,个性化医疗不仅能够取得出色疗效,还可以在短时间内落地。”
去年12月,罗茜接种了首剂抗癌疫苗,今年2月完成了加强针注射。目前,她体内的大部分肿瘤已经显著缩小。尽管肿瘤尚未完全消失,但罗茜的健康状况已经有所改善。
3月14日,索达森在X平台发布的帖子中称,罗茜的故事证明,技术能够让抗癌疫苗的设计研发流程“民主化”。
他提醒道,由于部分肿瘤对疫苗未产生反应,罗茜可能并未痊愈,但疫苗确实为她争取了更多时间。尽管如此,康宁汉姆还是会接受这一结果。
他对《澳大利亚人报》表示:“去年12月时,她精神萎靡,肿瘤给她带来了巨大负担。治疗六周后,我带她去狗狗公园,她一看见兔子,直接跳过围栏追了上去。我很清楚这并非根治之法,但我坚信,这种治疗显著延长了罗茜的生命,也极大地提升了她的生活质量。”
罗茜的抗癌故事震惊了科技界的部分从业者,同时也彰显了人工智能在医学领域实现突破性进展的潜力——它或许可以让曾经被视为“死刑判决”的绝症,转变为能够常规治疗的疾病。
OthersideAI的联合创始人及首席执行官马特·舒默于上周末在X平台转发了康宁汉姆与爱犬的相关报道。
他写道:“当我说世界很快将变得极度荒诞时,我指的正是这样的事情。未来这类事件只会越来越多,听起来也会愈发疯狂。”(财富中文网)
译者:中慧言-王芳
2024年,位于澳大利亚悉尼的科技创业者保罗·康宁汉姆的爱犬罗茜被诊断出癌症。尽管罗茜接受了化疗与手术,肿瘤却仍未消退,病情也愈发严重。
于是他借助人工智能技术,在澳大利亚科学家的协助下,成功地研发出一款定制化mRNA抗癌疫苗。如今,罗茜体内的大部分肿瘤已经缩小,这只小狗又开始追逐野兔了。
据《澳大利亚人报》(Australian)报道,OpenAI旗下的ChatGPT建议采用免疫疗法,并指引康宁汉姆联系新南威尔士大学(University of New South Wales)的拉马乔蒂基因组学中心(Ramaciotti Center for Genomics)。
虽然康宁汉姆没有医学背景,但他是一名电气与计算机工程师,是Core Intelligence Technologies公司的联合创始人,还曾经担任澳大利亚数据科学与人工智能协会(Data Science and AI Association of Australia)的理事。
在与这所大学取得联系后,他说服了该校的研究人员提供协助,并向新南威尔士大学支付了罗茜的基因组测序费用。随后,他便开始深入研究这份基因数据。
“我向ChatGPT寻求帮助,并制定了具体的实施计划。”康宁汉姆告诉《澳大利亚人报》。
他还使用了谷歌(Google)DeepMind开发的人工智能工具AlphaFold,寻找可以作为潜在治疗靶点的突变蛋白。尽管他最终找到了一款与罗茜病情高度适配的免疫疗法药物,但制药公司却拒绝提供相关药剂。
随后,纳米医学领域先驱、新南威尔士大学RNA研究所(RNA Institute)的主任帕尔·索达森介入,利用康宁汉姆的数据,在不到两个月的时间内,研发出一款定制化mRNA疫苗。
“这是全球首款专为犬类设计的个性化抗癌疫苗。”索达森对《澳大利亚人报》表示,“作为癌症免疫治疗领域的前沿技术,该技术终会应用于人类疾病治疗。罗茜的案例给我们的启示是,借助mRNA技术,个性化医疗不仅能够取得出色疗效,还可以在短时间内落地。”
去年12月,罗茜接种了首剂抗癌疫苗,今年2月完成了加强针注射。目前,她体内的大部分肿瘤已经显著缩小。尽管肿瘤尚未完全消失,但罗茜的健康状况已经有所改善。
3月14日,索达森在X平台发布的帖子中称,罗茜的故事证明,技术能够让抗癌疫苗的设计研发流程“民主化”。
他提醒道,由于部分肿瘤对疫苗未产生反应,罗茜可能并未痊愈,但疫苗确实为她争取了更多时间。尽管如此,康宁汉姆还是会接受这一结果。
他对《澳大利亚人报》表示:“去年12月时,她精神萎靡,肿瘤给她带来了巨大负担。治疗六周后,我带她去狗狗公园,她一看见兔子,直接跳过围栏追了上去。我很清楚这并非根治之法,但我坚信,这种治疗显著延长了罗茜的生命,也极大地提升了她的生活质量。”
罗茜的抗癌故事震惊了科技界的部分从业者,同时也彰显了人工智能在医学领域实现突破性进展的潜力——它或许可以让曾经被视为“死刑判决”的绝症,转变为能够常规治疗的疾病。
OthersideAI的联合创始人及首席执行官马特·舒默于上周末在X平台转发了康宁汉姆与爱犬的相关报道。
他写道:“当我说世界很快将变得极度荒诞时,我指的正是这样的事情。未来这类事件只会越来越多,听起来也会愈发疯狂。”(财富中文网)
译者:中慧言-王芳
In 2024, Sydney tech entrepreneur Paul Conyngham found out his dog Rosie had cancer. But after attacking the diagnosis with chemotherapy and surgery, the tumors persisted and Rosie got sicker.
So he turned to AI and eventually developed a custom a mRNA cancer vaccine with the help of Australian scientists. Most of Rosie’s tumors have shrunk, and the dog is back chasing rabbits.
OpenAI’s ChatGPT suggested immunotherapy and directed Conyngham to the University of New South Wales Ramaciotti Center for Genomics, according to a report in the Australian.
While Conyngham doesn’t have a background in medicine, he is an electrical and computing engineer who cofounded Core Intelligence Technologies. He was also a director for the Data Science and AI Association of Australia.
After reaching out to university, he convinced researchers there to help him and paid UNSW for Rosie’s genomic sequencing. Then he started digging into the DNA.
“I went to ChatGPT and came up with a plan on how to do this,” Conyngham told the Australian.
He also used AlphaFold, an AI tool from Google’s DeepMind, to find mutated proteins that could be potential targets for treatment. While an immunotherapy treatment that looked like a good fit for Rosie was identified, the drugmaker wouldn’t provide it.
Then nanomedicine medicine pioneer Pall Thordarson, director of UNSW’s RNA Institute, stepped in and used Conyngham’s data to develop a bespoke mRNA vaccine in less than two months.
“This is the first time a personalized cancer vaccine has been designed for a dog,” he told the Australian. “This is still at the frontier of where cancer immunotherapeutics are—and ultimately, we’re going to use this for helping humans. What Rosie is teaching us is that personalized medicine can be very effective, and done in a time-sensitive manner, with mRNA technology.”
Rosie got her first injection of the cancer treatment this past December, then received a booster in February. Most of her tumors have already shrunk dramatically. And while they haven’t disappeared, Rosie’s health has improved.
In a thread on X March 14, Thordarson said Rosie’s story demonstrates that technology can “democratize” the process of designing cancer vaccines.
He cautioned that Rosie may not be cured as some tumors haven’t responded to the vaccine, though it bought her more time. Still, Conyngham will take it.
“In December she had low energy because the tumors were creating a huge burden for her,” he told the Australian. “Six weeks post-treatment, I was at the dog park when she spotted a rabbit and jumped the fence to chase it. I’m under no illusion that this is a cure, but I do believe this ¬treatment has bought Rosie significantly more time and quality of life.”
Rosie’s journey has stunned some people in the tech world while also pointing to AI’s potential to produce breakthroughs in medicine, perhaps turning diagnoses once considered death sentences into routine ailments.
Matt Shumer, cofounder and CEO of OthersideAI, took to X over the weekend to flag a story about Conyngham and his dog.
“This is what I mean when I say the world is going to get very weird, very soon,” he wrote. “Expect more stories like this, each sounding increasingly more insane.”